[CAS NO. 1628606-05-2] Vimseltinib

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1628606-05-2]

Catalog

HY-136256

Brand

MCE

CAS

1628606-05-2

DESCRIPTION [1628606-05-2]

Overview

MDL	MFCD32858282
Molecular Weight	431.49
Molecular Formula	C23H25N7O2
SMILES	O=C1N(C)C(NC(C)C)=NC=C1C2=NC(C)=C(OC3=CC(C4=CN(C)N=C4)=NC=C3)C=C2

For research use only. We do not sell to patients.

Summary

Vimseltinib (DCC-3014) is a c-FMS ( CSF-IR ) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC ₅₀ s of <0.01 μM and 0.1-1 μM, respectively ^[1] .

IC50 & Target

IC50: <0.01 μM (c-FMS/CSF-IR), 0.1-1 μM (c-Kit) ^[1]

In Vitro

Vimseltinib is a c-FMS (CSF-IR) and c-Kit dual inhibitor with anti-cancer and anti-proliferative activities ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04242238	Memorial Sloan Kettering Cancer Center	Sarcoma\|Advanced Sarcoma\|High Grade Sarcoma\|Leiomyosarcoma\|Undifferentiated Pleomorphic Sarcoma\|Myxofibrosarcoma\|Dedifferentiated Liposarcoma	January 22, 2020	Phase 1
NCT03069469	Deciphera Pharmaceuticals LLC	Advanced Malignant Neoplasm\|Pigmented Villonodular Synovitis\|Giant Cell Tumor of Tendon Sheath\|Tenosynovial Giant Cell Tumor\|Tenosynovial Giant Cell Tumor, Diffuse	February 16, 2017	Phase 1\|Phase 2
NCT05059262	Deciphera Pharmaceuticals LLC	Tenosynovial Giant Cell Tumor\|Pigmented Villonodular Synovitis\|Giant Cell Tumor of Tendon Sheath\|Tenosynovial Giant Cell Tumor, Diffuse\|Tenosynovial Giant Cell Tumor, Localized	October 14, 2021	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 115.88 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3176 mL	11.5878 mL	23.1755 mL
5 mM	0.4635 mL	2.3176 mL	4.6351 mL
10 mM	0.2318 mL	1.1588 mL	2.3176 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3.5 mg/mL (8.11 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 3.5 mg/mL (8.11 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3.5 mg/mL (8.11 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Yumi Ahn, et al. 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145025A2.